Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd and Elgi Rubber Company Ltd have announced a special window for re-lodging transfer requests of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026. The window is open for a period of 1 year from February 5, 2026, to February 4, 2027. Shareholders are requested to update their KYC details and convert their physical shares into dematerialized form.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the details of securities dematerialized/rematerialized during the period.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has received USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, which are bioequivalent and therapeutically equivalent to the reference listed drug Fycompa Tablets. The product will be manufactured at Unit-IV of APL Healthcare and launched in Q3FY27.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has completed the acquisition of the Contract Research Services business of A1 Biochem Group through its wholly-owned subsidiary Apitoria Pharma Private Limited.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has acquired 100% ownership of A1 Biochem Labs LLC, a US-based contract research services provider, through its wholly-owned subsidiary A1 Biochem USA Inc.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has informed that Dr. Rajendra Gadikota, former promoter of A1 Biochem group, has subscribed to 89,94,500 equity shares and 2,41,05,500 Compulsory Convertibles Debentures of A1 Labs, a step down subsidiary of the Company, equaling to 20% stake on a fully diluted basis.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd's step-down subsidiary Acrotech Biopharma has launched ADQUEY in the U.S. market, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis. This marks Aurobindo's entry into the U.S. dermatology market and establishes a dedicated dermatology business unit.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has received an order from the Appellate Joint Commissioner (ST) confirming a demand of Rs. 4,60,28,908/-, including interest and penalty, related to the reversal of alleged excess claim of Input Tax Credit (ITC) for FY 2020-21. The company intends to file an appeal against the order.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced the closure of its trading window for designated persons, including promoters, directors, and employees, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half year ending on September 30, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has informed the exchanges that the US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary, has concluded with one procedural observation. The company will respond to the US FDA within the stipulated timeline.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd and BPL Limited have announced their 62nd Annual General Meeting (AGM) through Video Conferencing (VC) or Other Audio Visual Means (OAVM) facility, without the physical presence of members. The AGM will be held on September 25, 2026, and members can cast their votes electronically through remote e-voting services provided by NSDL.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary, Ávogent Lifesciences Private Limited, by its subsidiary Apitoria Pharma Private Limited. The new subsidiary will undertake manufacturing and marketing operations in India and foreign countries.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd's wholly owned subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US market, marking the first product from Aurobindo's inhalation pipeline to be commercialized in the US.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has informed the exchanges that the US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary, has concluded with three procedural observations. The company will respond to the US FDA within the stipulated timeline.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced the voting results of its 39th Annual General Meeting (AGM) held on August 27, 2026. All resolutions were approved by shareholders with a requisite majority. The company also announced the payment of an interim dividend of Rs.4/- per equity share.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd held its 39th Annual General Meeting (AGM) on August 27, 2026, through video conferencing. The meeting was attended by 86 members, and the requisite quorum was present. The Chairman, Mr. M.R. Kumar, conducted the proceedings and informed the members that the integrated Annual Report for the financial year 2025-26 was sent to them through electronic mode. The shareholders were also provided with the facility to cast their votes electronically through remote e-voting, and those present at the AGM were given an opportunity to cast their votes at the end of the meeting through poll (electronic).

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced its participation in an investor/analyst meet held on September 1-2, 2026 in Hong Kong. The meet is organized by Goldman Sachs Asia Leaders and will include one-on-one meetings and group meetings. The company's officials will be present to discuss the company's performance and future prospects. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced an investor/analyst meet scheduled on September 1, 2026, where officials will participate in one-on-one and group meetings. The meeting schedule is subject to change due to exigency.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has informed that the US FDA conducted a routine inspection at its wholly-owned subsidiary Lannett Company LLC, a US-based pharmaceutical company, from August 17-21, 2026, and concluded with four procedural observations. The company will respond to the US FDA within the stipulated timeline and is committed to maintaining robust quality and compliance standards.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has completed a US FDA inspection at Auro Peptides Ltd, a subsidiary, with only one observation related to facility and equipment maintenance. The company has initiated corrective action and will submit a formal response within the stipulated timeline.